鈉–葡萄糖協(xié)同轉(zhuǎn)運(yùn)蛋白2（SGLT2）抑制劑是近年來應(yīng)用于臨床的新型口服抗糖尿病藥物，主要通過抑制分布在腎臟腎小管處的SGLT2來阻止多余葡萄糖的重吸收，促進(jìn)尿糖排泄，從而降低循環(huán)血糖水平，同時發(fā)揮利鈉、利尿作用，對充血性心力衰竭也是一種新的治療選擇。隨著越來越多的人群受用，研究發(fā)現(xiàn)SGLT2抑制劑還具有降低心血管結(jié)局等多種心血管保護(hù)作用，不僅可使心衰患者受益，對心肌梗死也呈現(xiàn)出多效性，盡管相關(guān)機(jī)制目前只是推測。主要對SGLT2抑制劑治療心肌梗死的相關(guān)研究進(jìn)行綜述。

The sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new type of oral antidiabetic drug, which has been used in clinic in recent years. It mainly prevents the reabsorption of excess glucose by inhibiting SGLT2 distributed in renal tubules, promotes the excretion of urine glucose, so as to reduce the level of circulating blood glucose, and plays the role of natriuretic and diuretic. It is also a new treatment option for congestive heart failure. With more and more people using SGLT2 inhibitors, it has been found that SGLT2 inhibitors can also reduce cardiovascular outcomes and other cardiovascular protective effects, which can not only benefit the patients with heart failure, but also have multiple effects on myocardial infarction. Although the relevant mechanism is only speculated at present, the potential of SGLT2 inhibitors in the treatment of myocardial infarction is ready to come out. The research progress on effect of sodium - glucose co-transporter 2 inhibitors on myocardial infarction is reviewed in this paper.

R972